On ECHEMI
Home > Drugs > Hybio Pharmaceutical Co., Ltd.
Hybio Pharmaceutical Co., Ltd.
  • Founded in:

    2003-04-02
  • Country:

    China China
  • Address:

    Hanyu Innovation Industry Building, No. 7 Guansheng 4th Road, Guanlan High-tech Park, Longhua District, Shenzhen
  • Tax NO.:

    91440300748855818E
  • Registered Funds:

    883.241336 million yuan
  • Website:

  • Email:

Related Drugs
Oxytocin for injection
The main ingredient of this product is oxytocin. Structural formula: This product is a peptide chain consisting of 9 amino acids containing a disulfide bond. H-Cys-Tyr-Ile-Glu(NH2)-Asp(NH2)-Cys-Pro-Leu-Gly-NH2
Name Description Content CAS NO. Registered Holders
Oxytocin

It stimulates the contraction of uterine smooth muscles, simulates the contraction of uterus during normal delivery, and causes cervical dilation; it stimulates the contraction of mammary smooth muscles, which helps milk to be discharged from the breast, but does not increase the amount of milk secretion from the mammary gland.

More

It stimulates the contraction of uterine smooth muscles, simulates the contraction of uterus during normal delivery, and causes cervical dilation; it stimulates the contraction of mammary smooth muscles, which helps milk to be discharged from the breast, but does not increase the amount of milk secretion from the mammary gland.

50-56-6 29
Glucagon hydrochloride
Name Description Content CAS NO. Registered Holders
Glucagon

Extract from the above information

More

Extract from the above information

16941-32-5 5
Glucagon Hydrochloride for Injection
The main ingredient is synthetic glucagon hydrochloride.
Name Description Content CAS NO. Registered Holders
Glucagon

It can increase the amount of intracellular cAMp and enhance myocardial contractility, increase cardiac output and stroke work, but the effect is short-lived and must be administered intravenously. Its positive inotropic effect can still be exerted after administering sufficient doses of cardiac glycosides and will not cause arrhythmias.

More

It can increase the amount of intracellular cAMp and enhance myocardial contractility, increase cardiac output and stroke work, but the effect is short-lived and must be administered intravenously. Its positive inotropic effect can still be exerted after administering sufficient doses of cardiac glycosides and will not cause arrhythmias.

16941-32-5 5
Sodium aescinate
Name Description Content CAS NO. Registered Holders
Escin, monosodium salt

Extract from the above information

More

Extract from the above information

20977-05-3 7
Oxytocin solution
Name Description Content CAS NO. Registered Holders
Oxytocin

Extract from the above information

More

Extract from the above information

50-56-6 29
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.